GSK, Ionis hepatitis B functional cure breaks open market for followers

The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top